Study shows no link between HPV vaccine and Blood Clotting
The Human Papillomavirus shows no evidence of increasing Blood clot risk, according to a study by Statens Serum Institut in Copenhagen. The report features in the July 9th issue of Jama (The Journal of the American Medical Association). The report details the method in which the study was carried out. VTE or Venous thromboembolism is a condition in which a clot forms in a vein, a common example of this is a deep vein thrombosis. Blood clots are commonly linked to long stays in hospital due to how immobile the patient can become, they are also more likely to happen in pregnant women cancer patients or people using the contraceptive pill.
“Safety concerns can compromise immunization programs to the detriment of public health,”
The report was carried out after two reports were released by The U.S. Centers for Disease Control and Prevention (CDC) hinting at a link between the vaccine and blood clots. Scheller and colleagues were quick to begin the study after writing that “Safety concerns can compromise immunization programs to detriment of public health, and timely evaluations of such concerns are essential”. This lead in depth study being carried out.
The method outlined by the report states, that the research team firstly: Examined all records of women in Denmark between the ages of 100 and 44, from October 2006 to July 2013, the amount of women aged between 10 and 44 during that period was 1,613,798. Of this 500,345 women received at least one dose of the vaccine, they then identified 5,396 cases of VTE. This allowed them to rule out cases of pregnancy, major surgery, lower limb surgery as well as cancer diagnosis, leaving 4375 cases. From this 889 of the women received the vaccine. The research team went on to examine these cases using the SCCS method (self-controlled case series method) seeing how many VTE’s occurred during the 42 days after the immunization period.
The data was then broken down into time frames, in days after the vaccination but there was no significant statistical change, giving sufficient evidence to suggest that there is no greater risk to women who received the vaccine and those who did not.
The CDC recommends that boys and girls between to ages of 11 and 12 should receive the vaccine, given in the form of three shots over a six month period. To prevent an estimated 7,000 HPV- related cancer cases in the United States.
Read more from Forbes here .